Cell Blocks and the Milan System for Reporting Salivary Gland Cytopathology: A Meta-Analysis.

Diagn CytopatholAug 6, 2026 (epub)
Clinical ResearchPathology (Anatomic & Clinical)

Aada Närhi, David Kalfert, Henri Lagerstam et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the distribution of Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) categories and their associated risks of malignancy (ROM) in salivary gland fine-needle aspirations (FNAs) using cell block preparations. Analyzing five studies with 1132 FNA samples, the overall ROM for malignant categories was found to be 97.7%.

Key findings

  • Pooled ROM for malignant (MN) category was 97.7%.
  • Distribution of samples: 21.9% non-diagnostic (ND), 30.0% benign neoplasm (BN).
  • ROM for suspicious for malignancy (SM) was 84.8%.
  • ROM for atypia of undetermined significance (AUS) was 26.3%.

Why it matters

Understanding the distribution and risks of malignancy associated with MSRSGC categories can enhance diagnostic accuracy in salivary gland lesions, guiding clinical decision-making and management strategies.

Source

PubMed · PMID 42563504

Published in Diagn Cytopathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pathology (Anatomic & Clinical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.